Stericycle (NASDAQ:SRCL) Earns Market Perform Rating from Barrington Research

Barrington Research reaffirmed their market perform rating on shares of Stericycle (NASDAQ:SRCL – Get Rating) in a research report released on Tuesday morning, Zacks.com reports. Barrington Research also issued estimates for Stericycle’s Q1 2022 earnings at $0.42 EPS, Q2 2022 earnings at $0.51 EPS, Q3 2022 earnings at $0.49 EPS, Q4 2022 earnings at $0.63 EPS and FY2023 earnings at $2.46 EPS.

Other research analysts have also recently issued reports about the stock. Robert W. Baird lowered their target price on shares of Stericycle from $77.00 to $72.00 and set an outperform rating on the stock in a report on Friday, February 25th. StockNews.com downgraded shares of Stericycle from a buy rating to a hold rating in a research report on Thursday. Finally, Zacks Investment Research cut shares of Stericycle from a hold rating to a sell rating and set a $62.00 target price on the stock. in a research note on Tuesday, March 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, Stericycle currently has a consensus rating of Hold and a consensus price target of $67.00.

Shares of NASDAQ:SRCL opened at $53.41 on Tuesday. Stericycle has a 1 year low of $53.25 and a 1 year high of $79.97. The business has a fifty day simple moving average of $57.21 and a 200 day simple moving average of $59.78. The company has a current ratio of 0.79, a quick ratio of 0.79 and a debt-to-equity ratio of 0.66. The firm has a market cap of $4.92 billion, a price-to-earnings ratio of -172.28, a P/E/G ratio of 3.16 and a beta of 1.30.

Stericycle (NASDAQ:SRCL – Get Rating) last announced its quarterly earnings results on Thursday, February 24th. The business services provider reported $0.38 EPS for the quarter, missing analysts’ consensus estimates of $0.44 by ($0.06). Stericycle had a positive return on equity of 8.26% and a negative net margin of 1.05%. The business had revenue of $657.30 million for the quarter, compared to the consensus estimate of $662.25 million. During the same quarter in the prior year, the business earned $0.59 EPS. The firm’s revenue for the quarter was up .2% on a year-over-year basis. On average, sell-side analysts forecast that Stericycle will post 2.19 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of SRCL. Whittier Trust Co. of Nevada Inc. purchased a new stake in Stericycle during the third quarter worth approximately $31,000. Quent Capital LLC purchased a new position in shares of Stericycle in the 4th quarter worth about $33,000. First Horizon Advisors Inc. grew its stake in Stericycle by 1,369.2% during the 3rd quarter. First Horizon Advisors Inc. now owns 573 shares of the business services provider’s stock valued at $43,000 after purchasing an additional 534 shares in the last quarter. Covestor Ltd acquired a new stake in Stericycle during the 4th quarter valued at approximately $43,000. Finally, CastleArk Alternatives LLC acquired a new position in shares of Stericycle in the 3rd quarter worth approximately $52,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Stericycle Company Profile (Get Rating)

Stericycle, Inc, together with its subsidiaries, provides regulated and compliance solutions in the United States, Europe, and internationally. The company offers regulated waste and compliance services, including sharps disposable and management solutions; pharmaceutical waste services; hazardous waste disposal; maritime waste services, such as seaport and airport waste; and compliance programs under the Steri-Safe, Clinical Services, First Practice Management, SeguriMed, and EnviroAssure brand names.

See Also